We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mersana Therapeutics Inc | NASDAQ:MRSN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.38% | 2.61 | 2.55 | 2.60 | 2.72 | 2.45 | 2.67 | 5,346,704 | 23:40:08 |
Mersana Therapeutics, Inc. (NASDAQ:MRSN), today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16, 2017, from 10:20-10:50am EDT.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170809005756/en/
Mersana Therapeutics, Inc.Media ContactPaul Kidwell, 617-680-1088paulkidwell@comcast.netorInvestors ContactStern Investor Relations, Inc.Christina Tartaglia, 212-362-1200Christina@sternir.com
1 Year Mersana Therapeutics Chart |
1 Month Mersana Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions